Clinical Trial Update: Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD) [Phase 3]

View source ↗

Summary

A Phase 3, double-blind, randomized, placebo-controlled trial (Polaris-AD) is evaluating AR1001 in early Alzheimer's disease; the study is currently active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AR1001

Snippet

Sponsor: AriBio Co., Ltd. | Conditions: Alzheimer Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING